Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 70, Issue 2, Pages 201-212Publisher
WILEY
DOI: 10.1111/j.1365-2125.2010.03679.x
Keywords
AUC(0,24 h) : MIC; dosage individualization; intensive care unit; population pharmacokinetics; pharmacokinetics/pharmacodynamics or PK/PD; vancomycin
Categories
Ask authors/readers for more resources
AIM To estimate the vancomycin pharmacokinetic profile in adult ICU patients and to assess vancomycin dosages for increasing the likelihood of optimal exposure. METHODS Five hundred and sixty-nine concentration-time data from 191 patients were analysed using a population pharmacokinetic approach (NONMEN (TM)). External model evaluation was made in 46 additional patients. The 24 h area under the concentration-time curve (AUC(0,24 h)) was derived from the final model. Minimum inhibitory concentration (MIC) values for S. aureus were obtained from the EUCAST database. AUC(0,24 h) : MIC >= 400 was considered as PK/PD efficacy index. The probability of different dosages attaining the target considering different strains of S. aureus and patient subgroups was estimated with Monte Carlo simulation. RESULTS Vancomycin CL showed a significant dependence on patient age and renal function whereas Cr-Se > 1mg dl(-1) increased V more than twofold. For our representative ICU patient, 61 years, 73 kg, Cr-Se = 1.4 mg dl(-1), measured CLCr = 74.7 ml min(-1), the estimated values were CL = 1.06 ml min(-1) kg(-1) and V = 2.04 l kg(-1). The cumulative fraction of response for a standard vancomycin dose (2 g day(-1)) was less than 25% for VISA strains, and 33% to 95% for susceptible S. aureus, depending on patient characteristics. CONCLUSIONS Simulations provide useful information regarding the initial assessment of vancomycin dosing, the conventional dosing regimen probably being suboptimal in adult ICU patients. A graphic approach provides the recommended dose for any selected probability of attaining the PK/PD efficacy target or to evaluate the cumulative fraction of response for any dosing regimen in this population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available